Abstract:Personalized management of patients at risk ideally should involve a multidisciplinary team of not only genetic counselors and surgeons, but also women's health or menopause specialists, knowledgeable psychologists, and primary care providers or obstetrician-gynecologists aware of the risks and fears "previvors" (survivors of a predisposition to cancer who have not had the disease) face as well as the issues that are common postoperatively. Identification of patients at risk for hereditary cancer, understanding of current genetic testing modalities and potential results, knowledge about screening and prevention including timing of surveillance, preventive medication and risk-reducing surgeries, understanding limitations and comorbidities associated with these risk management strategies and long-term psychological support are all important in hereditary cancer management. We describe issues surrounding the identification of the high-risk patient, universal testing in breast and ovarian cancer, and testing in special populations. We describe a simplified approach to understanding and communicating genetic testing results and nuances of testing including direct-to-consumer testing. We highlight concerns surrounding breast cancer screening during pregnancy and lactation. A framework for practical management and counseling of women who opt for risk-reducing salpingo-oophorectomy or risk-reducing mastectomy or both is provided. We provide an in-depth discussion of questions that arise in relation to timing of surgery, fertility preservation, management of menopausal symptoms, and surgical technique. Alternative choices in women who choose to delay bilateral salpingo-oophorectomy are reviewed. Finally, the psychosocial effects of carrying a genetic mutation and the issues that women face when undergoing to risk-reducing surgery including adjustment, sexuality issues, and cosmesis are addressed.

Hereditary gynecologic tumors and precision cancer medicine

Rare Hereditary Gynecological Cancer Syndromes

Genetic Testing Enhances the Precision Diagnosis and Treatment of Breast Cancer

Hereditary non-BRCA gynecological tumors

Hereditary gynaecological malignancies: advances in screening and treatment

Uncommon hereditary gynaecological tumour syndromes: pathological features in tumours that may predict risk for a germline mutation

Current and future role of genetic screening in gynecologic malignancies

A New Paradigm Of Genetic Testing For Hereditary Breast/Ovarian Cancers

Hereditary and Familial Traits in Urological Cancers and Their Underlying Genes

A Clinical Guide to Hereditary Cancer Panel Testing: Evaluation of Gene-Specific Cancer Associations and Sensitivity of Genetic Testing Criteria in a Cohort of 165,000 High-Risk Patients.

Genetic Predisposition for Gynecologic Cancers

Recent advances in pediatric hereditary neoplastic syndromes

Hereditary Gastrointestinal Tumor Syndromes: When Risk Comes with Your Genes

Genetic testing for hereditary prostate cancer: Current status and limitations

Controversies in Hereditary Cancer Management

Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions

Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis

Hereditary breast and ovarian cancer: from genes to molecular targeted therapies

Uncommon variants detected via hereditary cancer panel and suggestions for genetic counseling

Cancer predisposition genes: molecular mechanisms and clinical impact on personalized cancer care: examples of Lynch and HBOC syndromes

Clinical availability and characteristics of multigene panel testing for recurrent/advanced gynecologic cancer